We are live on
!
Find out more
CC
Callan Capital Portfolio holdings
AUM
$1.35B
Turnover
17.35%
1-Year Est. Return
8.35%
This Fund
S&P 500
This Quarter
Est. Return
+4.96%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$904M
AUM Growth
+$40.3M
(+4.7%)
Cap. Flow
-$112K
Cap. Flow
% of AUM
-0.01%
Top 10 Holdings %
Top 10 Hldgs %
51.47%
Holding
194
New
10
Increased
69
Reduced
70
Closed
10
Avg Time Held
2.7
years
Top 10 Avg Time Held
2.7
years
Top 20 Avg Time Held
3.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$13.7M |
| 2 |
Schwab Fundamental International Large Company Index ETF
FNDF
|
+$9.31M |
| 3 |
Avantis US Small Cap Value ETF
AVUV
|
+$5.28M |
| 4 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$4.63M |
| 5 |
Schwab Fundamental Emerging Markets Large Company Index ETF
FNDE
|
+$4.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs ActiveBeta International Equity ETF
GSIE
|
+$12.3M |
| 2 |
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
|
+$8.15M |
| 3 |
Schwab US Broad Market ETF
SCHB
|
+$3.99M |
| 4 |
Avantis US Equity ETF
AVUS
|
+$3.64M |
| 5 |
iShares International Equity Factor ETF
INTF
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.87% |
| 2 | Technology | 4.06% |
| 3 | Healthcare | 1.11% |
| 4 | Financials | 1.02% |
| 5 | Consumer Discretionary | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $128K | 0.01% |
72,559
+4,552
| +7% | +$11.6K |
2022 Q4
2 quarters
|
|
177
DELISTED
Cidara Therapeutics
CDTX
| $117K | 0.01% |
5,173
| – | – |
2022 Q4
2 quarters
|
|
178
Allogene Therapeutics
ALLO
$453M
| $95.5K | 0.01% |
19,224
| – | – |
2022 Q4
2 quarters
|
|
179
Equillium
EQ
$75.5M
| $77.8K | 0.01% |
103,688
| – | – |
2022 Q4
2 quarters
|
|
|
INFI
180
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $33.4K | ﹤0.01% |
158,500
| – | – |
2022 Q4
2 quarters
|
|
|
SRXH
181
SRX Global
SRXH
$24.1M
| $30.1K | ﹤0.01% |
73
+51
| +232% | +$35.5K |
2022 Q4
2 quarters
|
|
182
Cardiff Oncology
CRDF
$70.1M
| $20K | ﹤0.01% |
13,587
| – | – |
2022 Q4
2 quarters
|
|
183
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $16.6K | ﹤0.01% |
800
| – | – |
2022 Q2
4 quarters
|
|
184
Vanguard Total Bond Market
BND
$163B
| – | – |
-9,493
| Closed | -$701K | – |
|
185
Citigroup
C
$208B
| – | – |
-5,971
| Closed | -$280K | – |
|
186
iShares California Muni Bond ETF
CMF
$4.98B
| – | – |
-5,459
| Closed | -$313K | – |
|
187
Chevron
CVX
$441B
| – | – |
-1,888
| Closed | -$308K | – |
|
188
Energy Transfer Partners
ET
$69.8B
| – | – |
-11,246
| Closed | -$140K | – |
|
189
General Motors
GM
$73.7B
| – | – |
-7,216
| Closed | -$265K | – |
|
|
BINI
190
DELISTED
Bollinger Innovations
BINI
| – | – |
0
| – | -$2.63K |
2023 Q1
1 quarter
|
|
191
Nike
NKE
$55.1B
| – | – |
-2,693
| Closed | -$330K | – |
|
192
Occidental Petroleum
OXY
$62.4B
| – | – |
-7,106
| Closed | -$444K | – |
|
193
Wells Fargo
WFC
$252B
| – | – |
-8,884
| Closed | -$332K | – |
|
|
NXGN
194
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| – | – |
-104,307
| Closed | -$1.82M | – |
|
Similar funds
PRO
MBA
SIA
AP
MW
SBIA
LC
TW
Callan Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Callan Capital held 194 positions worth $904M, up 4.7% from $864M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Callan Capital's Q2 2023 filing shows 10 new, 69 increased, 70 reduced and 10 closed positions. Its largest new stake was iShares Russell 2000 ETF: 4,571 shares worth $856K. The largest sale was Goldman Sachs ActiveBeta International Equity ETF, an estimated $12.3M.
By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, up from 91% a quarter earlier, followed by Technology and Healthcare.
- Callan Capital's largest Q2 2023 buy was iShares Russell 2000 ETF: 4,571 shares worth $856K.
- Callan Capital added most to Schwab Fundamental US Large Company Index ETF in Q2 2023, an estimated $13.7M increase.
- Callan Capital's biggest Q2 2023 reduction was Goldman Sachs ActiveBeta International Equity ETF, cutting an estimated $12.3M.
- Callan Capital fully exited NextGen Healthcare, Inc. Common Stock in Q2 2023, selling an estimated $1.82M.
- Callan Capital's ten largest holdings make up 51% of its $904M portfolio in Q2 2023.
- Callan Capital opened 10 new positions and closed 10 in Q2 2023.
- Callan Capital's portfolio value rose 4.7% quarter-over-quarter to $904M.
Based on Callan Capital's 13F filing for Q2 2023, filed 4 Aug 2023.